Sagimet Biosciences Inc. - Series A · NASDAQ:SGMT

Sagimet Biosciences Inc. - Series A — Sagimet Biosciences — Technical Presentation (June 2023)

16 slides from Sagimet Biosciences Inc. - Series A's technical presentation, Jun 23, 2023

  1. Slide 1: Denifanstat, a FASN inhibitor for biopsy-proven NASH: 26-week interim analysis of FASCINATE-2

    Slide 1: Denifanstat, a FASN inhibitor for biopsy-proven NASH: 26-week interim analysis of FASCINATE-2

    Denifanstat, a fatty acid synthase (FASN) inhibitor for the treatment of biopsy-proven NASH: A 26-week interim analysis of the FASCINATE-2 Phase 2b trial Rohit Loomba, MD, MHSc University of California, San Diego

  2. Slide 2: Disclosures

    Slide 2: Disclosures

    Disclosures Conflict of Interest Disclosure Statement RL serves as chair of the clinical advisory board for Sagimet Biosciences and a consultant or advisory board member for 89bio, Alnylam, Arrowhead Pharmaceuticals, AstraZeneca, Boehringer Ingelheim, Bristol-Myer Squibb, Cirius, CohBar, DiCerna, Ga

  3. Slide 3: Denifanstat: Differentiated Mechanism Targets Key Drivers of NASH

    Slide 3: Denifanstat: Differentiated Mechanism Targets Key Drivers of NASH

    Denifanstat: Differentiated Mechanism Targets Key Drivers of NASH Denifanstat is a FASN inhibitor ❶ Blocks steatosis via inhibiting de novo lipogenesis in hepatocytes ❷ Reduces inflammation via preventing immune cell activation ❸ Blunts fibrosis via inhibiting stellate cell activation 3 Proprietary

  4. Slide 4: FASCINATE-2 Phase 2b Biopsy Trial: Measuring Histological Improvement

    Slide 4: FASCINATE-2 Phase 2b Biopsy Trial: Measuring Histological Improvement

    FASCINATE-2 Phase 2b Biopsy Trial: Measuring Histological Improvement FASCINATE-2 Phase 2b Trial Design Primary endpoints (biopsy) Fully enrolled: 168 patients in U.S., Canada, and Europe • NAS ≥2 points improvement w/o worsening of fibrosis OR Denifanstat 50mg resolution of NASH w/o worsening of fi

  5. Slide 5: FASCINATE-2: MRI and PD Biomarkers at Week 26 Interim Analysis

    Slide 5: FASCINATE-2: MRI and PD Biomarkers at Week 26 Interim Analysis

    FASCINATE-2: MRI and PD Biomarkers at Week 26 Interim Analysis FASCINATE-2: IA at Week 26 Aim To perform an interim analysis of Denifanstat 50mg Non-Invasive Tests (NITs) in Screening FASCINATE-2 at week 26 Placebo Study weeks • To examine the efficacy of 0 26 52 50mg once-daily denifanstat  Baseli

  6. Slide 6: Interim Analysis Cohort Represents Target Patient Population

    Slide 6: Interim Analysis Cohort Represents Target Patient Population

    Interim Analysis Cohort Represents Target Patient Population FASCINATE-2 Phase 2b Interim Analysis Demographics Mean (SD) Placebo (22) Denifanstat (30) Combined Age (years) 56.8 ( 9.4) 56.1 (12.4) 56.4 (11.1) Female/Male (%) 14 (63.6%) / 8 (36.4%) 17 (56.7%) / 13 (43.3%) 31 (59.6%) / 21 (40.4%) Not

  7. Slide 7: Denifanstat Decreases Liver Fat

    Slide 7: Denifanstat Decreases Liver Fat

    Denifanstat Decreases Liver Fat Steatosis Biomarker – Liver Fat Findings to Date • Denifanstat induced statistically significant reduction of liver fat • 67% (p<0.001) MRI-PDFF response rate • About half of responders decreased liver fat by ≥50% • A relative reduction of liver fat ≥30% by MRI-PDFF h

  8. Slide 8: Denifanstat Reduces ALT and Induced Dual Response

    Slide 8: Denifanstat Reduces ALT and Induced Dual Response

    Denifanstat Reduces ALT and Induced Dual Response ALT and Dual Response Findings to Date ALT • ALT decrease suggests a decrease in inflammation with denifanstat • Denifanstat increased dual liver fat and ALT responder rate, which correlates strongly with liver biopsy response 8 Proprietary Informati

  9. Slide 9: Denifanstat Decreases Markers of Fibrosis and Cell Injury

    Slide 9: Denifanstat Decreases Markers of Fibrosis and Cell Injury

    Denifanstat Decreases Markers of Fibrosis and Cell Injury Fibrosis and Hepatocyte Injury Biomarkers Findings to Date PRO-C3 ELF score • PRO-C3 and ELF trends suggest a decrease of liver fibrosis with denifanstat • ELF score has prognostic value • CK-18 response suggests reduction in hepatocyte injur

  10. Slide 10: Denifanstat Decreases De Novo Lipogenesis

    Slide 10: Denifanstat Decreases De Novo Lipogenesis

    Denifanstat Decreases De Novo Lipogenesis Pharmacodynamic Biomarker Findings to Date De novo lipogenesis Tripalmitin Acetyl-CoA ACC • Tripalmitin is a triglyceride containing three molecules Malonyl-CoA of palmitate, the fully saturated fatty acid product Denifanstat FASN of FASN • Tripalmitin decre

  11. Slide 11: Denifanstat Improves Metabolic Health

    Slide 11: Denifanstat Improves Metabolic Health

    Denifanstat Improves Metabolic Health Metabolic Health Findings to Date LDL-C FGF21 • LDL-cholesterol decrease suggests cardiovascular benefit • FGF21 increase indicates denifanstat may improve insulin sensitivity 11 Proprietary Information of Sagimet Biosciences Inc * p<0.05, ** p<0.01

  12. Slide 12: Denifanstat Favorably Changes Circulating Lipid Composition

    Slide 12: Denifanstat Favorably Changes Circulating Lipid Composition

    Denifanstat Favorably Changes Circulating Lipid Composition Saturated di- and tri- glycerides are upregulated in NASH Denifanstat reverses this abnormality by reducing saturated DG/TG and increasing polyunsaturated DG/TG FASCINATE-2 lipidomic data reproduced Phase 2a findings 12 Proprietary Informat

  13. Slide 13: Denifanstat Reduces Lipotoxic Ceramides

    Slide 13: Denifanstat Reduces Lipotoxic Ceramides

    Denifanstat Reduces Lipotoxic Ceramides Ceramides are associated with CVD risk and elevated in NASH: denifanstat reverses this abnormality Denifanstat reverses this abnormality by reducing ceramides Improvements across multiple lipotoxic species are pronounced with denifanstat: this is a unique lipi

  14. Slide 14: Denifanstat Was Well Tolerated in the Interim Population

    Slide 14: Denifanstat Was Well Tolerated in the Interim Population

    Denifanstat Was Well Tolerated in the Interim Population Interim analysis patients – across both active and placebo groups: • Majority of adverse events were Grade 1 or 2; no Grade ≥3 drug-related AEs • No treatment related SAEs, no fatal SAEs FASCINATE-2 Phase 2b – Interim analysis data set Treatme

  15. Slide 15: FASCINATE-2 Interim Results Consistent with Positive Readouts from FASCINATE-1

    Slide 15: FASCINATE-2 Interim Results Consistent with Positive Readouts from FASCINATE-1

    FASCINATE-2 Interim Results Consistent with Comprehensive Positive Readouts from FASCINATE-1 Interim Results to date show: • Significant reduction in MRI-PDFF • Consistent dual response of liver fat & ALT; associated with NASH resolution DENIFANSTAT • Improvements observed in multiple biomarkers of

  16. Slide 16: THANK YOU to our investigators and site staff, patients and their families!

    Slide 16: THANK YOU to our investigators and site staff, patients and their families!

    THANK YOU to our investigators and site staff, patients and their families!

Source: company website

More decks from Sagimet Biosciences Inc. - Series A

All 34 Sagimet Biosciences Inc. - Series A decks